Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome - a randomized study (SYSDIET)

Journal of Internal Medicine

Volumn 274, Issue 1, 2013, Pages 52-66

  Uusitupa, M ^a,b   Hermansen, K ^c   Savolainen, M J ^d   Schwab, U ^a,b   Kolehmainen, M ^a   Brader, L ^c   Mortensen, L S ^c   Cloetens, L ^e   Johansson Persson, A ^e   Onning G ^e   Landin Olsson, M ^f   Herzig, K H ^b,d   Hukkanen, J ^d   Rosqvist, F ^g   Iggman, D ^g,h   Paananen, J ^a   Pulkki, K J ^a   Siloaho, M ^a,d   Dragsted, L ⁱ   Barri, T ⁱ   Overvad, K ^j,k   Bach Knudsen, K E ^j   Hedemann, M S ^j   Arner, P ^l   Dahlman, I ^l   Borge, G I A ^m   Baardseth, P ^m   Ulven, S M ⁿ   Gunnarsdottir, I ^o   Jonsdottir S ^o   Thorsdottir, I ^o   Oresic M ^o   Poutanen, K S ^a,p   Riserus U ^g   Akesson B ^e,f   more..

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF OULU   (Finland)

^e LUND UNIVERSITY   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

^h Center for Clinical Research Dalarna   (Sweden)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j AARHUS UNIVERSITY   (Denmark)

^k AALBORG UNIVERSITY HOSPITAL   (Denmark)

^l KAROLINSKA INSTITUTE   (Sweden)

^m NOFIMA   (Norway)

ⁿ OSLO METROPOLITAN UNIVERSITY   (Norway)

^o LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^p VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

more..

Author keywords

Cardiovascular risk; Inflammation; Intervention; Metabolic syndrome; Nordic diet

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; PHOSPHOLIPID; SATURATED FATTY ACID;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL FEATURE; DAIRY PRODUCT; DIETARY INTAKE; DISEASE MARKER; FEMALE; FOOD INTAKE; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NORDIC DIET; PHYSICAL ACTIVITY; PRIORITY JOURNAL; VEGETABLE;

EID: 84879123209     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12044     Document Type: Article

References (51)

1. Mozaffarian D, Appel LJ, Van Horn L. Components of a cardioprotective diet: new insights. Circulation 2011; 123: 2870-91.
2. Alberti KGMM, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung and, Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
3. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2010; 7: e1000252.
4. Katan MB, Zock P, Mensink RP. Effects of fats and fatty acids on blood lipids in humans: an overview. Am J Clin Nutr 1994; 60(Suppl): 1017S-22S.
5. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 2010; 6: 335-46.
6. Contois JH, McConnell JP, Sethi AA et al. Apolipoprotein B and cardiovascular risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group Best Practices. Clin Chem 2009; 55: 407-19.
7. Ramjee V, Sperling LS, Jacobson TA. Non-high density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification. Do the Math. J Am Coll Cardiol 2011; 58: 457-63.
8. Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-35.
9. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
10. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-12.
11. Lopez-Garcia E, Schulze MB, Fung TT et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2004; 80: 1029-35.
12. Basu A. Devaraj Sr, Jialal I. Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 995-1001.
13. Esposito K, Marfella R, Ciotola M et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome. A randomized trial. JAMA 2004; 292: 1440-6.
14. Salas-Salvadó J, Garcia-Arellano A, Estruch R et al. PRDIMET Investigators. Components of the Mediterranean-type food pattern and serum inflammatory markers among patients at high risk for cardiovascular disease. Eur J Clin Nutr 2008; 62: 651-9.
15. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status; meta-analysis. BMJ 2008; 337: a1344.
16. Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu FB. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 2009; 119: 1093-100.
17. Salas-Salvadó J, Bullo M, Babio N et al. PREDIMED Study Investigators. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011; 34: 14-9.
18. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr 1995; 61: S1402-19.
19. Papadaki A, Scott JA. The impact on eating habits of temporary translocation from a Mediterranean to a Northern European environment. Eur J Clin Nutr 2002; 56: 455-61.
20. Roininen K, Tuorila H, Zandstra EH et al. Differences in health and taste attitudes and reported behavior among Finnish, Dutch and British consumers: a cross-national validation of the Health and Taste Attitude Scales [HTAS]. Appetite 2001; 37: 33-45.
21. Bere E, Brug J. Towards health-promoting and environmentally friendly regional diets - a Nordic example. Public Health Nutr 2009; 12: 91-6.
22. Olsen A, Egeberg R, Halkjaer J, Christensen J, Overvad K, Tjonneland A. Healthy aspects of the Nordic diet are related to lower total mortality. J Nutr 2011; 141: 639-44.
23. Adamsson V, Reumark A, Fredriksson I-B et al. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolemic subjects: a randomized controlled trial [NORDIET]. J Intern Med 2011; 269: 150-9.
24. Jenkins DJ, Kendall CW, McKeown-Eyessen G et al. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA 2008; 300: 2742-53.
25. Spitzer RL, Yanovski S, Wadden T, Wing R, Marcus MD. Binge eating disorder: its further validation in a multisite study. Int J Eat Disord 1993; 13: 137-53.
26. Nordic Nutrition Recommendations. 4th Edition Intergrading Nutrition and Physical activityNord 2004:13. Copenhagen: Nordic Council of Ministers, 2004.
27. Boberg M, Croon LB, Gustafsson I-B, Vessby B. Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway. Clin Sci 1985; 68: 581-7.
28. Stancakova A, Javorsky M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M. Changes in insulin sensitivity and release in relation to glycemia and glucose tolerance in 6, 414 Finnish men. Diabetes 2009; 58: 1212-21.
29. de Mello VD, Schwab U, Kolehmainen M et al. A diet high in fatty fish, bilberries and wholegrain products improves markers of endothelial function and inflammation in individuals with impaired glucose metabolism in a randomised controlled trial: the Sysdimet study. Diabetologia 2011; 54: 2755-67.
30. Pinheiro J, Bates D, DebRoy S, Sarkar D; the R Development Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-102. Available at: http://cran.r-project.org/web/packages/nlme/ [accessed March 2012].
31. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2011. ISBN 3-900051-07-0, URL http://www.R-project.org/. Accessed March 30 2012.
32. Bonaa K. Epidemiological and intervention studies on the effect of marine polyunsaturated fatty acids on blood pressure. J Intern Med 1989; 225(Suppl 1): 105-10.
33. Iggman D, Gustafsson I-B, Berglund L, Vessby B, Marckmann P, Riserus U. Replacing dairy fat with rapeseed oil causes rapid improvement of hyperlipidaemia: a randomized controlled study. J Intern Med 2011; 270: 356-64.
34. Obarzanek E, Sacks FM, Vollmer WM et al. DASH Research group. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension [DASH] Trial. Am J Clin Nutr 2001; 74: 80-9.
35. Basu A, Rhone M, Lyons TJ. Berries: emerging impact on cardiovascular health. Nutr Rev 2010; 68: 168-77.
36. Erlund I, Koli R, Alfthan G et al. Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. Am J Clin Nutr 2008; 87: 323-31.
37. Frost G, Leeds AA, Dore CJ, Madeiros S, Brading S, Dornhorst A. Glycaemic index as a determinant of serum HDL-cholesterol concentration. Lancet 1999; 353: 1045-8.
38. Michalsen A, Lehmann N, Pithan C et al. Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary heart disease. Eur J Clin Nutr 2006; 60: 478-85.
39. Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-24.
40. Festa A, Hanley AJ, Tracy RP, D'Agostino R Jr, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003; 108: 1822-30.
41. Salmenniemi U, Ruotsalainen E, Pihlajamäki J et al. Multiple abnormalities in glucose tolerance and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004; 110: 3842-8.
42. Carstensen M, Herder C, Kivimäki M et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010; 59: 1222-7.
43. Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabak A. Elevated levels of anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes. Diabetes Care 2009; 32: 421-3.
44. Luotola K, Pietilä A, Zeller T et al. Associations between interleukin- [IL-1] gene variations or IL-receptor antagonist levels and the development of type 2 diabetes. J Intern Med 2010; 269: 322-32.
45. Hurme M, Santtila S. IL-1 receptor antagonist [IL-1Ra] plasma levels are co-ordinately regulated by both IL-Ra and IL-1 beta genes. Eur J Immunol 1998; 28: 2598-602.
46. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 1992; 263(3 Pt 2): R734-7.
47. Song Y, Li TY, van Dam RM, Manson JE, Hu FB. Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr 2007; 85: 1068-74.
48. Bjermo H, Iggman D, Kullberg J et al. Effect of n-6 polyunsaturated versus saturated fat on liver fat, lipoprotein metabolism and inflammation in abdominal obesity. A randomized controlled trial. Am J Clin Nutr 2012; 95: 1003-12.
49. Pihlajamäki J, Kuulasmaa T, Kaminska D et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol 2012; 56: 663-70.
50. Boekholdt SM, Arsenault BJ, Mora S et al. Association of LDL-cholesterol, non-HDL-cholesterol and apolipoprotein B levels with the risk of cardiovascular events among patients treated with statins. JAMA 2012; 307: 1302-9.
51. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness og lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol 2012; 110: 1468-76.